Human papillomavirus type 52 L1 capsid protein antigen

DB10313ApprovedInvestigationalVaccines

Human papillomavirus type 52L1 capsid protein antigen is contained in Gardasil is a vaccine for intramuscular injection. It is an immunization for young men and women 9-26 years of age...

First approval
Canada, 2015 · United States, 2014 · European Union, 2020
Also known as
L1 protein, Human papillomavirus type 52 Vaccine · Recombinant human papillomavirus type 52 L1 protein
Brand names
  • Gardasil 9

Resolves to

Compound
UNII55644W68FD
Clinical / RWD
RxNorm1596933

What you can answer from here — as of April 02, 2025

77Clinical trialsPhase, status and sponsor resolved per trial
Sign in
2Structured indicationsCondition, population, route and combination as fields, not prose
Sign in
20Marketed productsAcross 9 countries and 7 labellers
Sign in

Which other approved drugs treat the same conditions as Human papillomavirus type 52 L1 capsid protein antigen, and which companies have late-stage candidates in those indications?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In